Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- ArcStone US Corp.Alyea Therapeutics to Attend the ArcStone-Kingswood Growth Summit 2026 in TorontoAlyea Therapeutics, a wholly owned subsidiary of AIFC Corporation (NASDAQ: AIFC), is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Centre Toronto Hotel. Amol Soin, MD, Chief Executive Officer of Alyea Therapeutics, will participate as a Featured Company and will hold one-on-one meetings with interested investors and capital...
- MicrosoftInside the pharmaceutical industry’s AI shiftCompanies: MicrosoftThe post Inside the pharmaceutical industry’s AI shift appeared first on Source.
- MicrosoftHow pharmaceutical leaders are operationalizing AICompanies: MicrosoftThe post How pharmaceutical leaders are operationalizing AI appeared first on Source.
- Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)Company announcement No. 48 / 2026
- PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of DirectorsGross Proceeds of $11.3 Million at Initial Closing
- Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell CarcinomaAmeluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy platform
- Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory DiseasesFirst subjects dosed in Santa Ana Bio's Phase 1 study of SAB01, a first-in-class bispecific antibody targeting KIT and Siglec-6 for mast cell depletion.
- Revelyx Bio Reports Positive Topline Phase 2 Results for YY003, a Recombinant, Ready-to-Use Liquid Botulinum Toxin Type A, in Moderate-to-Severe Glabellar LinesRevelyx Bio, Inc., a clinical-stage biopharmaceutical company, today reported positive topline results from a Phase 2 clinical trial of YY003, an investigational recombinant botulinum toxin type A in a ready-to-use liquid formulation, in adults with moderate-to-severe glabellar lines. The trial met its primary endpoints and key secondary endpoints.
- Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual MeetingRAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint
- Alveus Therapeutics Initiates Phase 2 PRESERVE Trial to Evaluate ALV-100 for Chronic Weight ManagementAlveus Therapeutics Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, today announced the initiation of the Phase 2 PRESERVE trial and dosing of the first patient with ALV-100, its lead investigational therapy designed to address one of the most important unmet needs in obesity care: sustaining weight loss over time. The study will evaluate ALV-100 in adults with obesity or overweight who have achieved and stabilized their weight loss with semaglutide and are transitioning to long-term weight management.
- Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of AnaphylaxisClinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-administration to administration by a health care professional
- Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma ModelsTelomir Pharmaceuticals announces Ohio State research demonstrating Telomir-Zn inhibition of cell growth across human and canine osteosarcoma models.